Predicting Chemotherapy Toxicity in Older Adults with Cancer: a Prospective Multicenter Study
Overview
Authors
Affiliations
Purpose: Older adults are vulnerable to chemotherapy toxicity; however, there are limited data to identify those at risk. The goals of this study are to identify risk factors for chemotherapy toxicity in older adults and develop a risk stratification schema for chemotherapy toxicity.
Patients And Methods: Patients age ≥ 65 years with cancer from seven institutions completed a prechemotherapy assessment that captured sociodemographics, tumor/treatment variables, laboratory test results, and geriatric assessment variables (function, comorbidity, cognition, psychological state, social activity/support, and nutritional status). Patients were followed through the chemotherapy course to capture grade 3 (severe), grade 4 (life-threatening or disabling), and grade 5 (death) as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events.
Results: In total, 500 patients with a mean age of 73 years (range, 65 to 91 years) with stage I to IV lung (29%), GI (27%), gynecologic (17%), breast (11%), genitourinary (10%), or other (6%) cancer joined this prospective study. Grade 3 to 5 toxicity occurred in 53% of the patients (39% grade 3, 12% grade 4, 2% grade 5). A predictive model for grade 3 to 5 toxicity was developed that consisted of geriatric assessment variables, laboratory test values, and patient, tumor, and treatment characteristics. A scoring system in which the median risk score was 7 (range, 0 to 19) and risk stratification schema (risk score: percent incidence of grade 3 to 5 toxicity) identified older adults at low (0 to 5 points; 30%), intermediate (6 to 9 points; 52%), or high risk (10 to 19 points; 83%) of chemotherapy toxicity (P < .001).
Conclusion: A risk stratification schema can establish the risk of chemotherapy toxicity in older adults. Geriatric assessment variables independently predicted the risk of toxicity.
Geriatric Assessment Tools in Head and Neck Radiation Oncology: An Unmet Need.
McIver R, Ottensoser L, Parashar B Cureus. 2025; 17(3):e79979.
PMID: 40034421 PMC: 11875553. DOI: 10.7759/cureus.79979.
Use of adjuvant capecitabine in older patients with early-stage triple-negative breast cancer.
Sullivan M, Lei X, Karuturi M, Malinowski C, Giordano S, Chavez-MacGregor M Breast Cancer Res Treat. 2025; .
PMID: 40019667 DOI: 10.1007/s10549-025-07637-2.
Yeo M, Voutsadakis I J Clin Med. 2025; 14(4).
PMID: 40004631 PMC: 11856852. DOI: 10.3390/jcm14041099.
Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada.
Menjak I, Campos K, Pasetka M, Budden A, Curle E, Gibson L Curr Oncol. 2025; 32(2).
PMID: 39996889 PMC: 11853954. DOI: 10.3390/curroncol32020089.
Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type.
Brokaar E, Knikman J, Visser L, van den Bos F, Henricks L, Lunenburg C Fundam Clin Pharmacol. 2025; 39(2):e70000.
PMID: 39969252 PMC: 11837876. DOI: 10.1111/fcp.70000.